TitleAssociate Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wilke RN, Iniesta MD, Fellman B, Jazaeri AA, Meyer LA, Fleming ND, Schmeler KM, Taylor JS. A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery? Gynecol Oncol. 2024 Jun 29; 188:120-124. PMID: 38945019.
    2. How JA, Jazaeri AA. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies. Med. 2024 Jun 14; 5(6):487-489. PMID: 38878765.
      Citations:    Fields:    Translation:Humans
    3. Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, Clark N, Hillman RT, Campbell E, Holla V, Johnson AM, Biter AB, Yuan Y, Cobb LP, Gershenson DM, Jazaeri AA, Lu KH, Soliman PT, Westin SN, Euscher ED, Lawson BC, Yang RK, Meric-Bernstam F, Hong DS. Clinical and genomic landscape of RAS mutations in gynecologic cancers. Clin Cancer Res. 2024 Apr 30. PMID: 38687597.
      Citations:    Fields:    
    4. Knisely A, Hinchcliff EM, Gardiner E, Rangwala R, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 2024 May 17; 27(5):109801. PMID: 38726365; PMCID: PMC11079458.
    5. Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Apr 12; 5(4):311-320.e3. PMID: 38471508; PMCID: PMC11015975.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2). PMID: 38309721; PMCID: PMC10840042.
      Citations:    Fields:    Translation:HumansCells
    7. Vo D, Liu Y, Sood AK, Rezvani K, Jazaeri AA, Liu J, Vo D, Liu Y, Sood AK, Rezvani K, Jazaeri AA, Liu J. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma. Cancer Biomark. 2024; 39(4):289-298. PMID: 38250760; PMCID: PMC11091604.
      Citations:    Fields:    
    8. Bernard L, How JA, Patel S, Yates MS, Jazaeri A. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab. Gynecol Oncol. 2024 Jan; 180:139-145. PMID: 38091773.
      Citations:    Fields:    Translation:HumansCells
    9. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071. PMID: 38009662.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming ovarian cancer care by targeting minimal residual disease. Med. 2023 11 10; 4(11):755-760. PMID: 37951209.
      Citations:    Translation:Humans
    11. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 2024 02 01; 130(3):400-409. PMID: 37864520; PMCID: PMC10841432.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Ing BI, Kuhl D, Glassman D, Johnson CA, Patel S, Jazaeri AA. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer. Gynecol Oncol Rep. 2023 Dec; 50:101296. PMID: 37920829; PMCID: PMC10618414.
    13. Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623. PMID: 37104874; PMCID: PMC10322132.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    14. Disis ML, Adams SF, Bajpai J, Butler MO, Curiel T, Dodt SA, Doherty L, Emens LA, Friedman CF, Gatti-Mays M, Geller MA, Jazaeri A, John VS, Kurnit KC, Liao JB, Mahdi H, Mills A, Zsiros E, Odunsi K. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. J Immunother Cancer. 2023 06; 11(6). PMID: 37295818; PMCID: PMC10277149.
      Citations: 2     Fields:    Translation:Humans
    15. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562. PMID: 37248301.
      Citations: 26     Fields:    Translation:HumansCells
    16. Batman S, Rauh-Hain JA, Grinsfelder MO, Harrison R, Avila M, Cun H, How JA, Tandon N, Wang X, Hinchcliff E, Jazaeri AA, Schmeler KM. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report. Case Rep Oncol. 2023 Jan-Dec; 16(1):273-278. PMID: 37123608; PMCID: PMC10134052.
    17. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer. 2023 06 01; 129(11):1672-1680. PMID: 36930815.
      Citations:    Fields:    Translation:Humans
    18. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18. PMID: 36751659; PMCID: PMC9888522.
    19. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82. PMID: 36423446; PMCID: PMC9797438.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    20. Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol. 2022 Dec; 167(3):490-495. PMID: 36270831.
      Citations: 1     Fields:    
    21. Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol. 2022; 12:1001150. PMID: 36324592; PMCID: PMC9618687.
      Citations: 3     
    22. Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol. 2022 Dec; 167(3):483-489. PMID: 36229264.
      Citations: 2     Fields:    Translation:Humans
    23. Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145. PMID: 36137845.
    24. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel). 2022 Jul 29; 14(15). PMID: 35954359; PMCID: PMC9367373.
    25. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel). 2022 Jul 23; 14(15). PMID: 35892848; PMCID: PMC9330879.
    26. Fix SM, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA, Forget MA, Dominguez AL. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-? signaling. J Immunother Cancer. 2022 07; 10(7). PMID: 35882447; PMCID: PMC9330322.
      Citations:    Fields:    Translation:HumansCells
    27. Hinchcliff E, Gunther J, Ponnie AE, Bednarski B, Onstad M, Shafer A, Frumovitz M, Jazaeri A, Urbauer D, Bodurka DC. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. J Cancer Educ. 2022 06; 37(3):615-620. PMID: 32839894; PMCID: PMC8274252.
      Citations:    Fields:    Translation:Humans
    28. Son J, George GC, Nardo M, Krause KJ, Jazaeri AA, Biter AB, Hong DS. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecol Oncol. 2022 06; 165(3):664-670. PMID: 35400527; PMCID: PMC9133136.
      Citations:    Fields:    Translation:HumansCells
    29. Nash AM, Jarvis MI, Aghlara-Fotovat S, Mukherjee S, Hernandez A, Hecht AD, Rios PD, Ghani S, Joshi I, Isa D, Cui Y, Nouraein S, Lee JZ, Xu C, Zhang DY, Sheth RA, Peng W, Oberholzer J, Igoshin OA, Jazaeri AA, Veiseh O. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci Adv. 2022 03 04; 8(9):eabm1032. PMID: 35235346; PMCID: PMC8890714.
      Citations: 2     Fields:    Translation:Animals
    30. Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271. PMID: 35045973.
      Citations:    Fields:    Translation:HumansCells
    31. Sims TT, Jazaeri AA. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation. Int J Gynecol Cancer. 2021 11; 31(11):1408-1409. PMID: 34551893.
      Citations:    Fields:    Translation:Humans
    32. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365. PMID: 34518313; PMCID: PMC8639651.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    33. Corsini EM, Mitchell KG, Zhou N, Bernatchez C, Haymaker CL, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Amaria RN, Jazaeri AA, Antonoff MB, Forget MA. Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. J Surg Oncol. 2021 Sep; 124(4):699-703. PMID: 34057733.
      Citations: 1     Fields:    Translation:HumansCells
    34. Litwin RJ, Tam AL, Sheth RA, Yevich SM, Chan JL, Jazaeri AA, Halm JK, Gupta S, Huang SY. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. Abdom Radiol (NY). 2021 09; 46(9):4489-4498. PMID: 33999283.
      Citations:    Fields:    Translation:Humans
    35. How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31. PMID: 33958211; PMCID: PMC8222164.
      Citations: 3     Fields:    Translation:Humans
    36. Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol. 2021 07; 113:20-27. PMID: 33887301; PMCID: PMC8219231.
      Citations: 4     Fields:    Translation:Humans
    37. Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers (Basel). 2021 Apr 08; 13(8). PMID: 33917869; PMCID: PMC8068305.
      Citations: 3     
    38. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71. PMID: 33838925; PMCID: PMC8287765.
      Citations: 1     Fields:    Translation:Humans
    39. El Alam MB, Sims TT, Kouzy R, Biegert GWG, Jaoude JABI, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905. PMID: 33662003; PMCID: PMC7932122.
      Citations: 2     Fields:    Translation:HumansCells
    40. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Feb 24; 13(5). PMID: 33668244; PMCID: PMC7956737.
      Citations: 8     
    41. How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep. 2021 02 11; 11(1):3667. PMID: 33574401; PMCID: PMC7878854.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    42. Fix SM, Jazaeri AA, Hwu P. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. Cancer Discov. 2021 03; 11(3):560-574. PMID: 33563662; PMCID: PMC8193798.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    43. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835. PMID: 33415580; PMCID: PMC8076052.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    44. How JA, Patel A, Jazaeri AA. Immuno-Oncology for Gynecologic Malignancies. Adv Exp Med Biol. 2021; 1342:193-232. PMID: 34972966.
      Citations:    Fields:    Translation:Humans
    45. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97. PMID: 33154095; PMCID: PMC8266398.
      Citations: 1     Fields:    Translation:Humans
    46. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575. PMID: 32534809; PMCID: PMC7486997.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    47. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502. PMID: 32294438; PMCID: PMC7234854.
      Citations: 26     Fields:    Translation:Humans
    48. Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 04; 157(1):161-166. PMID: 31924334; PMCID: PMC7127981.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    49. How J, Patel A, Jazaeri A. Immuno-oncology for Gynecologic Malignancies. Adv Exp Med Biol. 2020; 1244:149-182. PMID: 32301014.
      Citations: 1     Fields:    Translation:Humans
    50. Hinchcliff E, Jazaeri AA. Sunset, or dawn of a new age for ovarian cancer vaccine therapy? Gynecol Oncol. 2019 12; 155(3):387-388. PMID: 31812214.
      Citations:    Fields:    Translation:Humans
    51. Roelands J, Garand M, Hinchcliff E, Ma Y, Shah P, Toufiq M, Alfaki M, Hendrickx W, Boughorbel S, Rinchai D, Jazaeri A, Bedognetti D, Chaussabel D. Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. Front Immunol. 2019; 10:2410. PMID: 31681299; PMCID: PMC6813721.
      Citations: 10     Fields:    Translation:HumansCells
    52. Sakellariou-Thompson D, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Bernatchez C, Forget MA, Haymaker C. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother. 2019 Nov; 68(11):1747-1757. PMID: 31602489; PMCID: PMC7269372.
      Citations: 5     Fields:    Translation:HumansCells
    53. Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR, Klopp A. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244. PMID: 31500892; PMCID: PMC6825899.
      Citations: 17     Fields:    Translation:Humans
    54. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. 2019 Sep; 68(9):1515-1526. PMID: 31515669; PMCID: PMC11028084.
      Citations: 9     Fields:    Translation:HumansCells
    55. Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA. B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecol Oncol Rep. 2019 Aug; 29:94-97. PMID: 31467959; PMCID: PMC6710557.
    56. Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, Difeo A, Scacheri PC, Adli M. Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. Cancer Res. 2019 09 15; 79(18):4599-4611. PMID: 31358529; PMCID: PMC6744966.
      Citations: 12     Fields:    Translation:HumansCells
    57. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer. 2019 05 03; 7(1):118. PMID: 31053161; PMCID: PMC6499962.
      Citations: 8     Fields:    Translation:Humans
    58. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019 04 02; 7(1):93. PMID: 30940209; PMCID: PMC6444537.
      Citations: 47     Fields:    Translation:Humans
    59. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019 02 06; 7(1):31. PMID: 30728076; PMCID: PMC6364483.
      Citations: 26     Fields:    Translation:Humans
    60. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413. PMID: 30366646; PMCID: PMC6281778.
      Citations: 7     Fields:    Translation:Humans
    61. Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102. PMID: 30283446; PMCID: PMC6156434.
      Citations: 13     Fields:    Translation:HumansCells
    62. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380. PMID: 30213435; PMCID: PMC6235625.
      Citations:    Fields:    Translation:Humans
    63. Johnson C, Jazaeri AA. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Clin Ther. 2018 03; 40(3):389-394. PMID: 29519715.
      Citations: 5     Fields:    Translation:Humans
    64. Jazaeri AA. Immunotherapy in ovarian cancer: where are we now, and where are we going? Clin Adv Hematol Oncol. 2017 Nov; 15(11):851-853. PMID: 29200418.
      Citations:    Fields:    Translation:Humans
    65. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086. PMID: 28901560.
      Citations: 12     Fields:    Translation:Humans
    66. Pakish JB, Jazaeri AA. Immunotherapy in Gynecologic Cancers: Are We There Yet? Curr Treat Options Oncol. 2017 08 24; 18(10):59. PMID: 28840453; PMCID: PMC5936621.
      Citations: 27     Fields:    Translation:Humans
    67. Qin Y, Ekmekcioglu S, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J, Forget MA. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689. PMID: 28670312; PMCID: PMC5473350.
      Citations: 28     Fields:    
    68. Nelson BH, Jazaeri AA. Immunotherapy for gynecological cancers: opportunities abound. Gynecol Oncol. 2017 06; 145(3):411-412. PMID: 28552394.
      Citations:    Fields:    Translation:Humans
    69. Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A. Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation. Mol Cancer Res. 2017 09; 15(9):1197-1205. PMID: 28550083; PMCID: PMC5581709.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    70. Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 May; 20:93-96. PMID: 28393092; PMCID: PMC5376265.
      Citations: 2     
    71. Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2017 02 28; 8(9):16099. PMID: 28403580; PMCID: PMC5362548.
      Citations:    Fields:    
    72. Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol. 2017 06; 145(3):462-468. PMID: 28233576.
      Citations: 10     Fields:    Translation:HumansCells
    73. Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016 09 30; 35(22):3892-906. PMID: 27112322; PMCID: PMC5012931.
      Citations: 10     Fields:    Translation:Humans
    74. Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol. 2016 Apr; 141(1):86-94. PMID: 27016233; PMCID: PMC5007873.
      Citations: 16     Fields:    Translation:HumansCells
    75. Ring KL, Pakish J, Jazaeri AA. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer J. 2016 Mar-Apr; 22(2):101-7. PMID: 27111905.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    76. Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA, Huang Z, Murphy SK, Mythreye K. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia. 2015 Nov; 17(11):826-38. PMID: 26678910; PMCID: PMC4681890.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    77. Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC, Gougeon A. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2015 Oct 06; 6(30):30194-211. PMID: 26327203; PMCID: PMC4745790.
      Citations: 4     Fields:    Translation:HumansCells
    78. Qiao Y, Quinlan AR, Jazaeri AA, Verhaak RG, Wheeler DA, Marth GT. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol. 2014 Aug 26; 15(8):443. PMID: 25160522; PMCID: PMC4180956.
      Citations: 32     Fields:    Translation:HumansCells
    79. Jividen K, Movassagh MJ, Jazaeri A, Li H. Two methods for establishing primary human endometrial stromal cells from hysterectomy specimens. J Vis Exp. 2014 May 23; (87). PMID: 24894444; PMCID: PMC4207099.
      Citations: 7     Fields:    Translation:HumansCells
    80. Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, Slack-Davis JK. Inhibition of a4?1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol. 2014 Feb; 132(2):455-61. PMID: 24378876; PMCID: PMC3939448.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    81. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther. 2013 Oct; 12(10):1958-67. PMID: 23939375; PMCID: PMC3795967.
      Citations: 38     Fields:    Translation:HumansCells
    82. Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, Jazaeri AA, Cantrell LA, Duska LR. Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. Gynecol Oncol Case Rep. 2013; 5:6-9. PMID: 24371682; PMCID: PMC3862329.
      Citations: 1     
    83. Bae-Jump V, Jazaeri A. Summary of the 2012 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2012 Aug; 126(2):174-5. PMID: 22588179.
      Citations:    Fields:    Translation:Humans
    84. Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA. Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol. 2012 Jul; 126(1):20-4. PMID: 22522190.
      Citations: 35     Fields:    Translation:Humans
    85. Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia. 2011 Oct; 13(10):899-911. PMID: 22028616; PMCID: PMC3201567.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    86. Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol. 2011 Apr; 121(1):2-7. PMID: 21269667.
      Citations: 4     Fields:    Translation:Humans
    87. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA. Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol. 2010 Dec; 116(6):1348-1353. PMID: 21099601.
      Citations: 5     Fields:    Translation:Humans
    88. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle. 2010 Nov 01; 9(21):4387-98. PMID: 20980827; PMCID: PMC3055190.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    89. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol. 2010 Aug 01; 118(2):189-95. PMID: 20462630.
      Citations: 13     Fields:    Translation:HumansCells
    90. Terai K, Abbas T, Jazaeri AA, Dutta A. CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell. 2010 Jan 15; 37(1):143-9. PMID: 20129063; PMCID: PMC2818832.
      Citations: 84     Fields:    Translation:HumansCells
    91. Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, Jazaeri AA. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer. 2010 Jan; 20(1):120-5. PMID: 20130512.
      Citations: 4     Fields:    Translation:Humans
    92. Jazaeri AA, Slack-Davis JK. The promise of antiangiogenic therapy for ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2273-4. PMID: 19907207.
      Citations: 3     Fields:    Translation:HumansAnimals
    93. Greene DP, Ferriss JS, Jazaeri AA. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother Pharmacol. 2010 Jul; 66(2):265-7. PMID: 19844714.
      Citations: 2     Fields:    Translation:Humans
    94. Jazaeri AA. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol. 2009 Apr; 3(2):151-6. PMID: 19383376; PMCID: PMC5527878.
      Citations: 6     Fields:    Translation:Humans
    95. Bland AE, Stone R, Heuser C, Shu J, Jazaeri A, Shutter J, Atkins K, Rice L. A clinical and biological comparison between malignant mixed m?llerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer. 2009 Feb; 19(2):261-5. PMID: 19396006.
      Citations: 11     Fields:    Translation:Humans
    96. Lachance JA, Shutter J, Atkins KA, Stoler MH, Rice LW, Jazaeri AA. Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol. 2008 Aug; 199(2):189.e1-6. PMID: 18501326.
      Citations: 2     Fields:    Translation:Humans
    97. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol. 2008 Apr; 109(1):140-5. PMID: 18275990.
      Citations: 15     Fields:    Translation:Humans
    98. Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol. 2008 Jan; 108(1):77-83. PMID: 17936341.
      Citations: 5     Fields:    Translation:Humans
    99. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother. 2007 Oct; 8(14):2293-305. PMID: 17927484.
      Citations: 11     Fields:    Translation:Humans
    100. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PMID: 17689649.
      Citations: 6     Fields:    Translation:Humans
    101. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol. 2007 Aug; 197(2):195.e1-7; discussion 195.e7-8. PMID: 17689647.
      Citations: 3     Fields:    Translation:Humans
    102. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol. 2006 Aug; 195(2):568-74; discussion 574-6. PMID: 16890558.
      Citations: 11     Fields:    Translation:Humans
    103. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed m?llerian tumors. Am J Obstet Gynecol. 2006 Apr; 194(4):1119-26; discussion 1126-8. PMID: 16580307.
      Citations: 5     Fields:    Translation:HumansCells
    104. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10. PMID: 16144934.
      Citations: 68     Fields:    Translation:Humans
    105. Irvin W, Evans SR, Andersen W, Jazaeri A, Taylor P, Stoler M, Pastore L, Rice L. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol. 2005 Aug; 193(2):559-65; discussion 565-7. PMID: 16098895.
      Citations: 3     Fields:    Translation:HumansCells
    106. Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. J Transl Med. 2004 Sep 21; 2(1):32. PMID: 15383145; PMCID: PMC520825.
      Citations: 6     Fields:    
    107. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 2003 Oct 15; 9(13):4811-8. PMID: 14581352.
      Citations: 39     Fields:    Translation:HumansCells
    108. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10393-8. PMID: 12917485; PMCID: PMC193572.
      Citations: 712     Fields:    Translation:Humans
    109. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog. 2003 Feb; 36(2):53-9. PMID: 12557260.
      Citations: 14     Fields:    Translation:Humans
    110. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003 Jan 01; 63(1):6-11. PMID: 12517768.
      Citations: 62     Fields:    Translation:Humans
    111. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002 Jul 03; 94(13):990-1000. PMID: 12096084.
      Citations: 77     Fields:    Translation:Humans
    112. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002; 4(3):R3. PMID: 12052255; PMCID: PMC111028.
      Citations: 44     Fields:    Translation:Humans
    113. Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn. 2002 Feb; 4(1):30-6. PMID: 11826185; PMCID: PMC1906976.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    114. Frailty. Obstetrical and Gynecological Survey. 68:30-32.
    115. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia (United States). 17:826-838.
    116. Immune checkpoint inhibitors in the treatment of gynecologic malignancies. Cancer Journal (United States). 22:101-107.
    117. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology. 141:86-94.
    118. BRCA1-mediated repression of select X chromosome genes. Journal of Translational Medicine. 2.
    119. Vulvar necrotizing soft tissue infection. Gynecologic Oncology Case Reports. 5:6-9.
    120. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 6:30194-30211.
    JAZAERI's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (383)
    Co-Authors (125)
    Similar People (60)
    Same Department Expand Description